Read by QxMD icon Read

Iron cera

Toru Kawai, Yoshie Kusano, Kyouko Yamada, Chikako Ueda, Atsushi Kawai, Takao Masaki
Recent evidence on maintenance administration of epoetin beta pegol, a continuous erythropoiesis receptor activator (CERA), in dialysis patients shows the clinical benefit of bi-weekly administration (Q2W) in improving hematopoiesis and iron use efficiency. We undertook a single-center observational study of 33 Japanese maintenance dialysis patients, whose anemia had been kept stable through weekly administration (Q1W) of darbepoetin (DA), to evaluate the effectiveness of CERA Q2W switched from DA in maintaining hemoglobin (Hb) levels over a 12-month period...
November 14, 2018: Journal of Artificial Organs: the Official Journal of the Japanese Society for Artificial Organs
Kazuya Takasawa, Chikako Takaeda, Takashi Wada, Norishi Ueda
Background: We determined optimal serum ferritin for oral iron therapy (OIT) in hemodialysis (HD) patients with iron deficiency anemia (IDA)/minor inflammation, and benefit of intravenous iron therapy (IIT) for OIT-nonresponders. Methods: Inclusion criteria were IDA (Hb <120 g/L, serum ferritin <227.4 pmol/L). Exclusion criteria were inflammation (C-reactive protein (CRP) ≥ 5 mg/L), bleeding, or cancer. IIT was withheld >3 months before the study. ΔHb ≥ 20 g/L above baseline or maintaining target Hb (tHB; 120-130 g/L) was considered responsive...
March 29, 2018: Nutrients
Zhigao Shen, Gianpiero Cera, Tobias Haven, Lutz Ackermann
The design of trisubstituted triazoles set the stage for proximity-induced iron-catalyzed C-H activation of benzyl and aryl amines with ample scope. Thereby, C-H alkylations and C-H arylations proved viable with high levels of chemo and positional selectivities by means of racemization-free iron catalysis with the reusable triazole being removed in a traceless fashion.
July 21, 2017: Organic Letters
G Cera, T Haven, L Ackermann
Iron-catalyzed C-H/N-H functionalizations were achieved by the aid of modular triazole amides. The alkyne annulation allowed for the expedient synthesis of valuable isoquinolone scaffolds with high levels of chemo-, site- and regio-selectivities.
June 13, 2017: Chemical Communications: Chem Comm
Gianpiero Cera, Tobias Haven, Lutz Ackermann
Triazole assistance enabled the first iron-catalyzed C-H alkynylation of arenes, heteroarenes, and alkenes. The modular TAM directing group set the stage for a sequential C-H alkynylation/annulation strategy with ample scope, enabling the iron-catalyzed assembly of isoquinolones, pyridones, pyrrolones, and isoindolinones with high levels of chemo-, site-, and regioselectivity.
March 13, 2017: Chemistry: a European Journal
Gianpiero Cera, Lutz Ackermann
Iron-catalyzed C-H activation has recently emerged as an increasingly powerful tool for the step-economical transformation of unreactive C-H bonds. Particularly, the recent development of low-valent iron catalysis has set the stage for novel C-H activation strategies via chelation assistance. The low-cost, natural abundance, and low toxicity of iron prompted its very recent application in organometallic C-H activation catalysis. An overview of the use of iron catalysis in C-H activation processes is summarized herein up to May 2016...
October 2016: Topics in Current Chemistry (Journal)
Hirokazu Honda, Yasuna Kobayashi, Shoko Onuma, Keigo Shibagaki, Toshitaka Yuza, Keiichi Hirao, Toshinori Yamamoto, Naohisa Tomosugi, Takanori Shibata
BACKGROUND: We aimed to identify associations between erythroferrone (ERFE), a regulator of hepcidin 25, and biomarkers of erythropoiesis and iron metabolism. We also aimed to determine the effects of erythropoiesis-stimulating agents (ESA), continuous erythropoietin receptor activator (CERA) and darbepoetin-α (DA) on ERFE production in patients on hemodialysis (HD). METHODS: Blood samples were obtained from 59 patients before HD sessions on day 0 (baseline). Twenty patients who were injected with either CERA (N = 10) or DA (N = 10) at the end of the dialysis week (day 0), who had ferritin ≥ 100 ng/mL and/or transferrin saturation ≥ 20%, and hemoglobin > 9 g/dL were selected from among the 59 patients...
2016: PloS One
Xiaobin Wu, Heejeong Kim, Javier Seravalli, Joseph J Barycki, P John Hart, David W Gohara, Enrico Di Cera, Won Hee Jung, Daniel J Kosman, Jaekwon Lee
Acquisition and distribution of metal ions support a number of biological processes. Here we show that respiratory growth of and iron acquisition by the yeast Saccharomyces cerevisiae relies on potassium (K(+)) compartmentalization to the trans-Golgi network via Kha1p, a K(+)/H(+) exchanger. K(+) in the trans-Golgi network facilitates binding of copper to the Fet3p multi-copper ferroxidase. The effect of K(+) is not dependent on stable binding with Fet3p or alteration of the characteristics of the secretory pathway...
April 29, 2016: Journal of Biological Chemistry
Tetsuya Furukawa, Kazuyoshi Okada, Masanori Abe, Ritsukou Tei, Osamu Oikawa, Noriaki Maruyama, Takashi Maruyama
Continuous erythropoietin receptor activator (CERA) seems to maintain a stable hemoglobin (Hb) level because its half-life is longer than darbepoetin α (DA). Twenty chronic kidney disease (CKD) patients at the pre-dialysis stage who had been administered DA for over 24 weeks were randomly assigned to receive subcutaneous CERA or DA once every four weeks during 48 weeks. In both groups, the rate of achievement of target Hb level changed from 70% to 100% in weeks 0 to 48, with no significant difference between the groups...
December 18, 2015: International Journal of Molecular Sciences
Chiharu Ito, Tetsu Akimoto, Yoshiyuki Morishita, Hisashi Yamamoto, Manabu Ogura, Tomoyuki Yamazaki, Atsushi Miki, Sumiko Homma, Eiji Kusano, Yasushi Asano, Daisuke Nagata
BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are the mainstay of treatment for renal anemia in chronic kidney disease (CKD) patients. However, the difference in hematopoietic effect between darbepoetin alfa (DA) and continuous erythropoiesis receptor activator (CERA) has remained unclear in non-dialysis CKD patients. Another purpose of this study was to analyze the red blood cells indices under treatment with these two ESAs in ESA-naïve CKD patients. METHODS: This study was designed as a multicenter retrospective observational investigation, and included 61 patients receiving DA (group DA) and 36 patients receiving CERA (group CERA) for at least six months...
2015: Nihon Jinzo Gakkai Shi
Gianpiero Cera, Tobias Haven, Lutz Ackermann
Triazole assistance set the stage for a unified strategy for the iron-catalyzed C-H allylation of arenes, heteroarenes, and alkenes with ample scope. The versatile catalyst also proved competent for site-selective methylation, benzylation, and alkylation with challenging primary and secondary halides. Triazole-assisted C-H activation proceeded chemo-, site-, and diastereo-selectively, and the modular TAM directing group was readily removed in a traceless fashion under exceedingly mild reaction conditions.
January 22, 2016: Angewandte Chemie
Michinori Hirata, Yoshihito Tashiro, Ken Aizawa, Ryohei Kawasaki, Yasushi Shimonaka, Koichi Endo
The increased deposition of iron in the kidneys that occurs with glomerulopathy hinders the functional and structural recovery of the tubules and promotes progression of chronic kidney disease (CKD). Here, we evaluated whether epoetin beta pegol (continuous erythropoietin receptor activator: CERA), which has a long half-life in blood and strongly suppresses hepcidin-25, exerts renoprotection in a rat model of chronic progressive glomerulonephritis (cGN). cGN rats showed elevated urinary total protein excretion (uTP) and plasma urea nitrogen (UN) from day 14 after the induction of kidney disease (day 0) and finally declined into end-stage kidney disease (ESKD), showing reduced creatinine clearance with glomerulosclerosis, tubular dilation, and tubulointerstitial fibrosis...
December 2015: Physiological Reports
Shoko Onuma, Hirokazu Honda, Yasuna Kobayashi, Toshinori Yamamoto, Tetsuo Michihata, Keigo Shibagaki, Toshitaka Yuza, Keiichi Hirao, Naohisa Tomosugi, Takanori Shibata
Continuous erythropoietin receptor activator (CERA) and darbepoetin-α (DA) might differently affect iron metabolism and erythropoiesis in patients on hemodialysis (HD). This prospective study examined a cohort of patients on HD who had received either intravenous CERA every 2 or 4 weeks (N = 25) or DA once each week (N = 47). Blood was sampled before HD sessions on days 0, 2, 4, 7 and 14, and on days 0, 3, 5, 7 and 14 from patients who were injected with ESA at the beginning and end of the dialysis week, respectively...
December 2015: Therapeutic Apheresis and Dialysis
Naoki Washida, Shuji Inoue, Takahiro Kasai, Keisuke Shinozuka, Koji Hosoya, Kohkichi Morimoto, Shu Wakino, Koichi Hayashi, Hiroshi Itoh
New erythropoiesis-stimulating agents with a longer half-life have been developed for the treatment of anemia in patients with end-stage renal disease. This study evaluated the efficacy of darbepoetin alfa (DA) and long-acting epoetin beta pegol (continuous erythropoietin receptor activator, CERA) in patients on peritoneal dialysis (PD). Twenty-nine patients who had undergone PD for at least 6 months and were iron replacement-naïve and negative for inflammatory parameters were enrolled. Hemoglobin (Hgb) levels and blood pressure were evaluated before and after switching from DA to CERA...
October 2015: Therapeutic Apheresis and Dialysis
Bidyut Akhuli, Luca Cera, Barun Jana, Subrata Saha, Christoph A Schalley, Pradyut Ghosh
A novel linear hybrid tris-bidentate neutral ligand having 2,2'-bipyridine and two terminal triazolylpyridine coordination sites (L) was efficiently synthesized and explored in the synthesis of trinuclear triple-stranded homometallic side-by-side helicates L3Fe3(OTf)6 (1) and L3Zn3(OTf)6 (2), in which the three metal centers display alternating Λ and Δ configurations. Selective formation of the analogous heterometallic side-by-side helicate L3Fe2Zn(OTf)6 (3) was achieved from a mixture of L, Fe(CH3CN)2(OTf)2, and Zn(OTf)2 (1:1:1) in acetonitrile at room temperature...
May 4, 2015: Inorganic Chemistry
Tomoyuki Otsuka, Yukinao Sakai, Shizuka Yui, Masami Sukegawa, Anna Suzuki, Koji Mugishima, Yuichiro Sumi, Yusuke Otsuka, Shuichi Tsuruoka
BACKGROUND: Sustained erythropoiesis-stimulating agents (ESAs) have recently been identified as the standard therapeutic agent for anemia in patients undergoing peritoneal dialysis (PD). However, few reports have compared pain between various types of sustained ESAs or between administration routes. Furthermore, the change ratio of the dose of sustained ESAs reportedly ranges from 0.8 to 1.3. In the present study, to compare darbepoetin alfa and epoetin beta pegol (a continuous erythropoietin receptor activator [CERA]), we examined the dolorific differences between administration routes and the effect on anemia by using a chjange ratio of 0...
2015: Journal of Nippon Medical School, Nippon Ika Daigaku Zasshi
A Sánchez-Escuredo, F Batista, A Cases, J-V Torregrosa
INTRODUCTION: Anemia after kidney transplantation (KT) has a negative impact on graft and patient survival. Anemia management includes iron supplements and erythropoiesis-stimulating agents (ESAs). Most ESAs require short frequency of administration and conversion to ESAs with longer half-life are complex. OBJECTIVE: This study was performed to assess the efficacy of continuous erythropoietin receptor activator (CERA) in hemoglobin (Hb) maintenance after conversion from shorter-acting ESAs with a simple conversion scheme in kidney transplant recipients...
January 2015: Transplantation Proceedings
Yuki Morikami, Akira Fujimori, Shioko Okada, Mai Kumei, Noriko Mizobuchi, Makoto Sakai
Epoetin beta pegol is a continuous erythropoietin receptor activator (CERA) with a long half-life. Although CERA has been shown to maintain adequate hemoglobin (Hb) levels at prolonged dosing intervals, the optimal dosing schedule remains unclear. We therefore compared the efficacy of maintaining hemoglobin levels with administration of twice-monthly CERA (TWICE) versus once-monthly CERA (ONCE). Twenty hemodialysis patients receiving epoetin beta (EPO) were enrolled in this crossover study. Patients were assigned to either the TWICE or the ONCE group based on matching Hb levels and EPO doses...
April 2015: Therapeutic Apheresis and Dialysis
Tadashi Kuji, Yoshiyuki Toya, Tetsuya Fujikawa, Midori Kakimoto-Shino, Masahiro Nishihara, Kazuhiko Shibata, Kouichi Tamura, Nobuhito Hirawa, Hidehisa Satta, Sei-ichi Kawata, Naoaki Kouguchi, Satoshi Umemura
This study aimed to evaluate the effect of different timings of iron administration during erythropoiesis activated by continuous erythropoietin receptor activator (CERA) on reticulocyte iron uptake in hemodialysis patients. In total, 110 patients were randomized to receive 40 mg intravenous elemental iron doses at all three hemodialysis sessions in the first week (IW1 group: n = 57) or in the third week (IW3 group: n = 53) after CERA administration. Following CERA administration at day 0, reticulocyte count increased, peaking at day 7...
April 2015: Therapeutic Apheresis and Dialysis
Yuki Morikami, Akira Fujimori, Shioko Okada, Mai Kumei, Noriko Mizobuchi, Makoto Sakai
Epoetin beta pegol (a continuous erythropoietin receptor activator; CERA) is usually administered once in 4 weeks or once monthly. However, the optimal dosing interval remains unknown. We, therefore, compared the effect of CERA administration between dosing intervals of 2 weeks (TWICE group) and 4 weeks (ONCE group) on erythropoiesis and iron metabolism in 20 hemodialysis patients. CERA was administered intravenously at weeks 0 and 2 for the TWICE group, and at week 0 for the ONCE group. Levels of hemoglobin (Hb), reticulocyte count, ferritin, transferrin saturation, content of Hb in reticulocytes and hepcidin-25 were monitored weekly for 4 weeks...
October 2014: Therapeutic Apheresis and Dialysis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"